Rapid growth of 20% in gene sequencing

Since last year, "precision medical care" has been competing with each other's capital. At present, there are 26 listed companies involved. An agency study estimates that the global “precise medical” market in 2015 will be approximately US$60 billion, and its growth rate in the next five years is expected to be 15%, which is three to four times that of the overall growth rate of the pharmaceutical industry. The growth rate of the gene sequencing industry will exceed 20%.

With the opening of the “two-child” policy, older pregnant women have become a needless group for non-invasive DNA testing, and have also increased the market for genetic testing products.

As the leading gene sequencing company in the Mainland, the benefits of BGI gene to the stock market are evident. The doubling of the valuation in the past two years has been "embraced" by many institutional investors.

The huge market space also made gene sequencing companies spring up. Last year, Yang Yong, who had a long-term investment vision, withdrew from Alibaba Vocational Education. He had no medical professional background. He integrated the “Genetic Aircraft Carrier” gene and other gene detection and tumor treatment technologies, and established the first precision testing company in the Mainland. Treatment and rehabilitation integrated self-service platform company Guanshi Company, including fertility, oncology, and sub-health fields.

Currently, on the World Health Watch, Hollywood heraldry Angelina Jolie's hereditary tumour test can be completed at home. Saliva samples can be reduced from 20,000 to 6,000 yuan in previous years, and the middle class is completely acceptable.

"I think the definition of 'precision medical' is that you know yourself better than anyone else." Yang Yong is very confident in this market, and the direction of "precision medical care" in the future must be self-recovery.